PLRX PLIANT THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, PLIANT THERAPEUTICS INC reported revenue of n/a, net income of −$22.4M and diluted EPS of −$0.36; for the fiscal year ended December 2025 revenue was $0.

PLRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$156M, net income $149M (margin n/a), EPS −$2.43
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$228M, net income $210M (margin n/a), EPS −$3.47
• Fiscal year ended Dec 2023: revenue $1.58M, gross profit n/a, operating income −$184M, net income $161M (margin 10208.9%), EPS −$2.75
• Fiscal year ended Dec 2022: revenue $9.69M, gross profit n/a, operating income −$127M, net income −$123M (margin -1273.3%), EPS −$2.94
• Fiscal year ended Dec 2021: revenue $7.57M, gross profit n/a, operating income −$97.5M, net income −$97.3M (margin -1284.5%), EPS −$2.71

PLRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$22.4M, EPS −$0.36
• Quarter ended Mar 31, 2026: revenue n/a, net income −$20.0M, EPS −$0.32
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $275M, EPS −$0.37
• Quarter ended Sep 30, 2025: revenue n/a, net income −$26.3M, EPS −$0.43
• Quarter ended Jun 30, 2025: revenue n/a, net income −$43.3M, EPS −$0.71
• Quarter ended Mar 31, 2025: revenue n/a, net income −$56.2M, EPS −$0.92
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income $371M, EPS −$0.82
• Quarter ended Sep 30, 2024: revenue $0, net income −$57.8M, EPS −$0.95
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$55.9M, EPS −$0.92
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$47.0M, EPS −$0.78
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income $282M, EPS −$0.68
• Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$41.5M, EPS −$0.70
• Quarter ended Jun 30, 2023: revenue $248K (down 95.0% year over year), net income −$41.2M, EPS −$0.70
• Quarter ended Mar 31, 2023: revenue $1.33M (up 6.6% year over year), net income −$37.5M, EPS −$0.67
• Quarter ended Dec 31, 2022 (from the annual report): revenue $1.97M (down 1.7% year over year), net income −$35.1M, EPS −$0.69
• Quarter ended Sep 30, 2022: revenue $1.48M (down 8.0% year over year), net income −$30.6M, EPS −$0.65
• Quarter ended Jun 30, 2022: revenue $4.99M (up 178.9% year over year), net income −$29.5M, EPS −$0.82
• Quarter ended Mar 31, 2022: revenue $1.25M (down 42.5% year over year), net income −$28.1M, EPS −$0.78
• Quarter ended Dec 31, 2021 (from the annual report): revenue $2.00M, net income −$24.5M, EPS −$0.68
• Quarter ended Sep 30, 2021: revenue $1.61M, net income −$27.0M, EPS −$0.75

PLRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$128M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow −$156M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$116M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$94.6M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2021: operating cash flow −$75.4M, share buybacks n/a

PLRX balance sheet

• Jun 30, 2026: cash $24.9M, total assets $190M, total liabilities $43.0M, shareholders' equity $147M
• Mar 31, 2026: cash $22.2M, total assets $203M, total liabilities $37.4M, shareholders' equity $165M
• Dec 31, 2025: cash $45.4M, total assets $225M, total liabilities $44.0M, shareholders' equity $181M
• Sep 30, 2025: cash $93.7M, total assets $277M, total liabilities $76.3M, shareholders' equity $200M
• Jun 30, 2025: cash $86.8M, total assets $300M, total liabilities $79.7M, shareholders' equity $220M
• Mar 31, 2025: cash $91.9M, total assets $345M, total liabilities $87.6M, shareholders' equity $257M
• Dec 31, 2024: cash $71.2M, total assets $397M, total liabilities $92.9M, shareholders' equity $304M
• Sep 30, 2024: cash $79.6M, total assets $446M, total liabilities $99.8M, shareholders' equity $346M

What is PLRX's revenue?

PLIANT THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.

Is PLRX profitable?

Yes. PLIANT THERAPEUTICS INC earned $206M over the last four quarters.

What is PLRX's EPS?

Diluted earnings per share over the last four quarters were −$1.48; −$0.36 in the latest quarter.

PLRX ownership and insider trades · All stocks